Alternating Electric Fields (TTFields) Inhibit Metastatic Spread of Solid Tumors to the Lungs

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2009 Apr 24

PMID 19387848

Citations 65

Authors

Eilon D Kirson

Moshe Giladi

Zoya Gurvich

Aviran Itzhaki

Daniel Mordechovich

Rosa S Schneiderman

Yoram Wasserman

Bernhard Ryffel

Dorit Goldsher

Yoram Palti

Affiliations

Soon will be listed here.

Abstract

Tumor treating fields (TTFields) are low intensity, intermediate frequency, alternating electric fields used to treat cancerous tumors. This novel treatment modality effectively inhibits the growth of solid tumors in vivo and has shown promise in pilot clinical trials in patients with advanced stage solid tumors. TTFields were tested for their potential to inhibit metastatic spread of solid tumors to the lungs in two animal models: (1) Mice injected with malignant melanoma cells (B16F10) into the tail vein, (2) New Zealand White rabbits implanted with VX-2 tumors within the kidney capsule. Mice and rabbits were treated using two-directional TTFields at 100-200 kHz. Animals were either monitored for survival, or sacrificed for pathological and histological analysis of the lungs. The total number of lung surface metastases and the absolute weight of the lungs were both significantly lower in TTFields treated mice then in sham control mice. TTFields treated rabbits survived longer than sham control animals. This extension in survival was found to be due to an inhibition of metastatic spread, seeding or growth in the lungs of TTFields treated rabbits compared to controls. Histologically, extensive peri- and intra-tumoral immune cell infiltration was seen in TTFields treated rabbits only. These results raise the possibility that in addition to their proven inhibitory effect on the growth of solid tumors, TTFields may also have clinical benefit in the prevention of metastatic spread from primary tumors.

Citing Articles

Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study.

Woo P, Pu J, Li L, Wong D, Hui V, Chan D J Neurooncol. 2025; .

PMID: 40067514 DOI: 10.1007/s11060-025-04985-3.

Tumor-treating fields and concurrent cisplatin: an demonstration of efficacy in triple-negative breast cancer.

Smothers A, Beasley M, Warren H, Kegel O, Edenfield W, OConnell J Am J Cancer Res. 2025; 15(1):322-330.

PMID: 39949927 PMC: 11815381. DOI: 10.62347/LXJH5896.

Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects.

Rafiq Z, Kang M, Barsoumian H, Manzar G, Hu Y, Leuschner C J Exp Clin Cancer Res. 2025; 44(1):31.

PMID: 39881333 PMC: 11781074. DOI: 10.1186/s13046-025-03281-2.

The Synergy of Thermal and Non-Thermal Effects in Hyperthermic Oncology.

Minnaar C, Szigeti G, Szasz A Cancers (Basel). 2024; 16(23).

PMID: 39682096 PMC: 11639953. DOI: 10.3390/cancers16233908.

Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?.

Pagliari G, Colonese F, Canova S, Abbate M, Sala L, Petrella F Cancers (Basel). 2024; 16(23).

PMID: 39682081 PMC: 11639858. DOI: 10.3390/cancers16233892.

References

Lavrenkov K, Man S, Geffen D, Cohen Y . Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. Isr Med Assoc J. 2002; 4(3):176-7. View

Suresh S . Biomechanics and biophysics of cancer cells. Acta Biomater. 2007; 3(4):413-38. PMC: 2917191. DOI: 10.1016/j.actbio.2007.04.002. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

vanSonnenberg E, Shankar S, Morrison P, Nair R, Silverman S, Jaklitsch M . Radiofrequency ablation of thoracic lesions: part 2, initial clinical experience--technical and multidisciplinary considerations in 30 patients. AJR Am J Roentgenol. 2005; 184(2):381-90. DOI: 10.2214/ajr.184.2.01840381. View

Whiteside T . The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45):5904-12. PMC: 3689267. DOI: 10.1038/onc.2008.271. View

Billingsley K, Burt M, Jara E, Ginsberg R, Woodruff J, Leung D . Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999; 229(5):602-10; discussion 610-2. PMC: 1420804. DOI: 10.1097/00000658-199905000-00002. View

McMILLAN T, Hart I . Can cancer chemotherapy enhance the malignant behaviour of tumours?. Cancer Metastasis Rev. 1987; 6(4):503-19. DOI: 10.1007/BF00047465. View

Kirson E, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y . Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004; 64(9):3288-95. DOI: 10.1158/0008-5472.can-04-0083. View

Nakada S, Jerde T, Warner T, Lee F . Comparison of cryotherapy and nephrectomy in treating implanted VX-2 carcinoma in rabbit kidneys. BJU Int. 2004; 94(4):632-6. DOI: 10.1111/j.1464-410X.2004.05015.x. View

10.

Walton B . Effects of anaesthesia and surgery on immune status. Br J Anaesth. 1979; 51(1):37-43. DOI: 10.1093/bja/51.1.37. View

11.

Friedel G, Pastorino U, Buyse M, Ginsberg R, Girard P, Goldstraw P . [Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases--the International Registry of Lung Metastases]. Zentralbl Chir. 1999; 124(2):96-103. View

12.

Suh R, Reckamp K, Zeidler M, Cameron R . Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology (Williston Park). 2005; 19(11 Suppl 4):12-21. View

13.

Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G . The anticancer immune response: indispensable for therapeutic success?. J Clin Invest. 2008; 118(6):1991-2001. PMC: 2396905. DOI: 10.1172/JCI35180. View

14.

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

15.

Rose S, Thistlethwaite P, Sewell P, Vance R . Lung cancer and radiofrequency ablation. J Vasc Interv Radiol. 2006; 17(6):927-51. DOI: 10.1097/01.RVI.0000222707.44902.66. View

16.

Kirson E, Schneiderman R, Dbaly V, Tovarys F, Vymazal J, Itzhaki A . Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009; 9:1. PMC: 2647898. DOI: 10.1186/1756-6649-9-1. View

17.

Sternberg D, Sonett J . Surgical therapy of lung metastases. Semin Oncol. 2007; 34(3):186-96. DOI: 10.1053/j.seminoncol.2007.03.004. View

18.

Atzpodien J, Kirchner H, Illiger H, Metzner B, Ukena D, Schott H . IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer. 2001; 85(8):1130-6. PMC: 2375150. DOI: 10.1054/bjoc.2001.2076. View

19.

Zhang S, Zeng Z, Tang Z, Sun J, Cheng J, Liu R . Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. Hepatol Int. 2009; 2(2):237-43. PMC: 2716849. DOI: 10.1007/s12072-008-9052-7. View

20.

Khan J, McElhinney D, Rahman S, George T, Clark O, Merrick S . Pulmonary metastases of endocrine origin: the role of surgery. Chest. 1998; 114(2):526-34. DOI: 10.1378/chest.114.2.526. View